Dermapharm Holding SE

DB:DMP

Germany / Healthcare / Pharmaceuticals

Overview

Dividends

10Y Historical Financials

Stock Price

36.65 EUR


Key Metrics	Latest
Total Revenue	1.195 B
Adjusted EBITDA	250.8 M
EBITDA Margin	21.0%
Net Profit Margin	9.8%
Total Assets	2.08 B
Total Debt	990.3 M

10Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months

Revenue	396	455	480	584	714	808	960	1,041	1,151	1,195	1,195
% Growth		14.9%	5.4%	21.8%	22.3%	13.1%	18.8%	8.4%	10.6%	3.9%

Adjusted EBITDA	75	90	95	120	131	155	312	302	220	251	251
% Margin	19.0%	19.7%	19.8%	20.6%	18.3%	19.2%	32.5%	29.1%	19.1%	21.0%	21.0%

Adjusted EBIT	70	85	90	113	120	140	296	283	193	222	222
% Margin	17.7%	18.6%	18.7%	19.3%	16.9%	17.3%	30.8%	27.2%	16.8%	18.6%	18.6%

Adjusted Net Income	48	76	77	79	78	88	209	162	67	117	117
% Margin	12.1%	16.6%	16.1%	13.4%	10.9%	10.9%	21.8%	15.6%	5.8%	9.8%	9.8%

Adjusted Basic EPS	NA	1.51	1.54	1.47	1.45	1.64	3.88	3.01	1.25	2.18	2.18

Supporting Calculations

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
											Original
EUR	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24
	FY - 9	FY - 8	FY - 7	FY - 6	FY - 5	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM

Revenue	396	455	480	584	714	808	960	1,041	1,151	1,195	1,195
% Growth	NA	14.9%	5.4%	21.8%	22.3%	13.1%	18.8%	8.4%	10.6%	3.9%

Cost of Revenue	(213)	(255)	(260)	(289)	(337)	(354)	(350)	(392)	(447)	(446)	(446)
Gross Profit	183	200	219	295	377	454	610	649	704	750	750
% Revenue	46.2%	43.9%	45.7%	50.5%	52.8%	56.2%	63.6%	62.3%	61.2%	62.7%	62.7%

Research and Development	(5)	(5)	(7)	(6)	(2)	(6)	(20)	(21)	(20)	(23)	(23)
Selling and Marketing	(7)	(7)	(9)	0	0	0	0	0	0	0	0
General and Admin	(58)	(63)	(69)	(92)	(116)	(158)	(169)	(191)	(271)	(287)	(287)
Other Inc / (Exp)	(90)	(35)	(41)	(88)	(141)	(156)	(123)	(209)	(255)	(223)	(223)
Total Operating Exp	(160)	(111)	(126)	(186)	(259)	(320)	(312)	(420)	(546)	(533)	(533)

Operating Income	23	89	93	108	118	134	298	228	158	216	216
% Revenue	5.8%	19.5%	19.5%	18.6%	16.5%	16.6%	31.0%	21.9%	13.8%	18.1%	18.1%

Interest Expense	(7)	(6)	(5)	(4)	(8)	(9)	(5)	(12)	(52)	(44)	(44)
Pre-tax Income	16	83	88	104	110	125	293	216	106	172	172
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0	0	0	0
Provision for Taxes	(3)	(6)	(10)	(29)	(32)	(39)	(84)	(84)	(45)	(60)	(60)
Net Income to Company	13	77	78	75	78	86	209	133	61	112	112
% Margin	3.3%	16.9%	16.2%	12.9%	10.9%	10.6%	21.8%	12.7%	5.3%	9.3%	9.3%

Minority Interest in Earnings	(0)	(0)	0	0	(1)	(0)	1	2	2	2	2
Net Income to Stockholders	13	77	78	75	77	86	210	134	62	114	114

Preferred Dividends	0	0	0	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0	0	0	0

Net Income to Common	13	77	78	75	77	86	210	134	62	114	114
% Margin	3.2%	16.9%	16.2%	12.9%	10.8%	10.6%	21.8%	12.9%	5.4%	9.5%	9.5%

As Reported
Basic EPS (Continuing Ops)	0.00	1.54	1.56	1.41	1.43	1.59	3.89	2.49	1.16	2.11	2.11
Diluted EPS (Continuing Ops)	0.00	1.54	1.56	1.41	1.43	1.59	3.89	2.49	1.16	2.11	2.11

WA Basic Shares Out.	0.00	49.88	49.94	53.42	53.84	53.84	53.84	53.84	53.84	53.84	53.84
WA Diluted Shares Out.	0.00	49.88	49.94	53.42	53.84	53.84	53.84	53.84	53.84	53.84	53.84

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	16	83	88	104	110	125	293	216	106	172	172
Addback: Net Interest Expense	7	6	5	4	8	9	5	12	52	44	44
Addback: Other Non Operating Expenses, Total	(0)	(2)	(3)	(0)	2	3	(2)	14	26	(2)	(2)
Addback: Depreciation & Amortization	5	5	5	8	10	15	16	20	27	29	29
Addback: Restructuring Charges	0	0	0	0	0	0	1	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	5	0	0	0	0	0	5	36	0	2	2
Addback: Gain (Loss) On Sale Of Invest.	0	(0)	0	0	0	0	(9)	0	2	0	0
Addback: Gain (Loss) On Sale Of Assets	3	0	0	0	0	(0)	(1)	(3)	(3)	(1)	(1)
Addback: Asset Writedown	0	0	0	6	2	4	4	7	16	6	6
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
Addback: Legal Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	39	(1)	(1)	(2)	(1)	0	0	0	(6)	0	0
Adjusted EBITDA	75	90	95	120	131	155	312	302	220	251	251
% Margin	19.0%	19.7%	19.8%	20.6%	18.3%	19.2%	32.5%	29.1%	19.1%	21.0%	21.0%

Adjusted EBIT	70	85	90	113	120	140	296	283	193	222	222
% Margin	17.7%	18.6%	18.7%	19.3%	16.9%	17.3%	30.8%	27.2%	16.8%	18.6%	18.6%

Adjusted Net Income Reconciliation
Net Income to Company	13	77	78	75	78	86	209	133	61	112	112
Addback: Unusual Items	47	(2)	(1)	5	0	3	(0)	40	9	8	8
Less: Tax Benefit of Unusual Items (26%)	(12)	1	0	(1)	(0)	(1)	0	(10)	(2)	(2)	(2)
Adjusted Net Income	48	76	77	79	78	88	209	162	67	117	117
% Margin	12.1%	16.6%	16.1%	13.4%	10.9%	10.9%	21.8%	15.6%	5.8%	9.8%	9.8%

Loading Error

Dermapharm Holding SE

DB:DMP

Germany / Healthcare / Pharmaceuticals

10Y Historical Financials